DE69531934D1 - Hydrophobe arzneistoffabgabesysteme - Google Patents

Hydrophobe arzneistoffabgabesysteme

Info

Publication number
DE69531934D1
DE69531934D1 DE69531934T DE69531934T DE69531934D1 DE 69531934 D1 DE69531934 D1 DE 69531934D1 DE 69531934 T DE69531934 T DE 69531934T DE 69531934 T DE69531934 T DE 69531934T DE 69531934 D1 DE69531934 D1 DE 69531934D1
Authority
DE
Germany
Prior art keywords
drug delivery
delivery systems
hydrophobic drug
dosage form
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531934T
Other languages
English (en)
Other versions
DE69531934T2 (de
Inventor
Edward M Rudnic
John A Mccarty
George W Belenduik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Shire Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Laboratories Inc filed Critical Shire Laboratories Inc
Publication of DE69531934D1 publication Critical patent/DE69531934D1/de
Application granted granted Critical
Publication of DE69531934T2 publication Critical patent/DE69531934T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
DE69531934T 1994-03-18 1995-03-15 Hydrophobe arzneistoffabgabesysteme Expired - Lifetime DE69531934T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/210,014 US5430021A (en) 1994-03-18 1994-03-18 Hydrophobic drug delivery systems
US210014 1994-03-18
PCT/US1995/003212 WO1995025505A1 (en) 1994-03-18 1995-03-15 Hydrophobic drug delivery systems

Publications (2)

Publication Number Publication Date
DE69531934D1 true DE69531934D1 (de) 2003-11-20
DE69531934T2 DE69531934T2 (de) 2004-09-02

Family

ID=22781263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531934T Expired - Lifetime DE69531934T2 (de) 1994-03-18 1995-03-15 Hydrophobe arzneistoffabgabesysteme

Country Status (10)

Country Link
US (1) US5430021A (de)
EP (1) EP0750494B1 (de)
JP (1) JPH09510708A (de)
AT (1) ATE251895T1 (de)
AU (1) AU703950B2 (de)
CA (1) CA2185802C (de)
DE (1) DE69531934T2 (de)
DK (1) DK0750494T3 (de)
ES (1) ES2210286T3 (de)
WO (1) WO1995025505A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
JP3471977B2 (ja) * 1995-06-02 2003-12-02 信越化学工業株式会社 液体状可塑剤を用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
DE19521974A1 (de) * 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
WO1997002815A1 (fr) * 1995-07-07 1997-01-30 Nippon Kayaku Kabushiki Kaisha Composition de flutamide
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
ES2236943T3 (es) 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
CA2311918A1 (en) * 1997-12-03 1999-06-10 Nippon Suisan Kaisha, Ltd. Coating layer agent for microwave-heated frozen food comprising food substrate and coating and/or sheet, and food using the same
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
BR9907195A (pt) * 1998-01-22 2000-10-10 Abbott Lab " formulações de tiagabina de liberação prolongada com efeitos colaterais reduzidos "
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US5869704A (en) * 1998-08-24 1999-02-09 Eastman Chemical Company Water-dispersible or water-soluble D-tocotrienol compounds and methods for making therefor
IL143580A0 (en) 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
JP2002534370A (ja) 1998-12-30 2002-10-15 デクセル リミテッド サイクロスポリンを送達するための分散可能な濃縮物
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6384248B1 (en) * 2000-08-17 2002-05-07 Fan Tech Ltd Meadowfoam based sorbitan esters
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
IL156532A0 (en) * 2000-12-27 2004-01-04 Ares Trading Sa Lipid microparticles, their preparation and pharmaceutical compositions containing them
WO2002072150A2 (en) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
JP2004532847A (ja) * 2001-04-20 2004-10-28 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア 疎水性薬物のためのミセル薬物送達システム
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
IL164152A0 (en) * 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1708687A1 (de) * 2004-01-16 2006-10-11 Glaxo Group Limited Einkapselung auf lipid basierender formulierung in magensaftresistenten polymeren
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20050260303A1 (en) * 2004-03-08 2005-11-24 Tritch Daniel L Sports drink
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060008527A1 (en) * 2004-07-09 2006-01-12 Yury Lagoviyer Controlled phase composition technology as an improved process for protection of drugs
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EA200701246A1 (ru) * 2004-12-09 2008-06-30 Инсис Терапьютикс, Инк. Стабильные при комнатной температуре составы дронабинола
GB2426703B (en) * 2005-05-31 2007-09-19 Malvern Cosmeceutics Ltd Compositions
JP2009502841A (ja) * 2005-07-26 2009-01-29 グラクソ グループ リミテッド 脂質をベースにした製剤の腸溶性ポリマー中へのカプセル化
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2659775A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
KR20080047957A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 고혈압의 치료 및 예방을 위한 약제 조성물
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
EP2268274B1 (de) 2008-03-20 2012-05-16 Virun, Inc. Vitamin-e-derivate und ihre verwendungen
CN107080734B (zh) 2008-03-20 2020-10-30 维尔恩公司 包含生育酚的peg衍生物的乳剂
WO2010008475A2 (en) * 2008-06-23 2010-01-21 Virun, Inc. Compositions containing nono-polar compounds
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
KR101634833B1 (ko) 2008-10-22 2016-06-29 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US10210216B2 (en) * 2009-12-18 2019-02-19 Sybase, Inc. Dynamic attributes for mobile business objects
CN103037708B (zh) 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
EP2918588B1 (de) 2010-05-20 2017-05-03 Array Biopharma, Inc. Makrocyclische Verbindungen als TRK-Kinasehemmer
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
WO2012033478A1 (en) * 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
EP2811847B1 (de) 2012-02-10 2017-12-13 Virun, Inc. Zubereitungen für getränke enthaltend neutrale verbindungen
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
JP7061602B2 (ja) 2016-04-04 2022-04-28 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤
WO2017201241A1 (en) 2016-05-18 2017-11-23 Mark Reynolds Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3599899A1 (de) 2017-03-23 2020-02-05 Virun, Inc. Stabile trockenpulver und emulsionen mit probiotika und mucoadhäsivem protein
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
JP2547995B2 (ja) * 1987-01-26 1996-10-30 昭和電工株式会社 反すう動物用粒剤及びその製造法
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
DE3838094A1 (de) * 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
US4971804A (en) * 1989-02-02 1990-11-20 Warner-Lambert Company Water dispersible gemfibrozil compositions
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
JPH048366A (ja) * 1990-04-26 1992-01-13 Dainichiseika Color & Chem Mfg Co Ltd 顆粒状芳香脱臭剤
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
US5234695A (en) * 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery

Also Published As

Publication number Publication date
EP0750494B1 (de) 2003-10-15
CA2185802A1 (en) 1995-09-28
EP0750494A4 (de) 1998-05-20
ATE251895T1 (de) 2003-11-15
AU1992595A (en) 1995-10-09
EP0750494A1 (de) 1997-01-02
JPH09510708A (ja) 1997-10-28
DK0750494T3 (da) 2004-01-19
US5430021A (en) 1995-07-04
ES2210286T3 (es) 2004-07-01
DE69531934T2 (de) 2004-09-02
AU703950B2 (en) 1999-04-01
WO1995025505A1 (en) 1995-09-28
CA2185802C (en) 2009-12-22

Similar Documents

Publication Publication Date Title
DE69531934D1 (de) Hydrophobe arzneistoffabgabesysteme
CA2103306A1 (en) Extrudable compositions for topical or transdermal drug delivery
WO1997014806A3 (en) Delivery of biologically active polypeptides
DE69805001T2 (de) Osmotische darreichungsform mit zwei mantelschichten
DE69302933D1 (de) Arzneimittelabgabesystem
FR2740686B1 (fr) Formulation pharmaceutique lyophilisee stable
DE19882286T1 (de) Intravesikale Medikamentenabgabesysteme
ATE201989T1 (de) Arzneimittel mit kontrollierter wirkstoffabgabe
FI961437A (fi) Vaikuttavan aineen luovuttava systeemi
ES2170501T3 (es) Composicion farmaceutica antivirica que comprende acido glicirrizico y al menos una proteina que posee actividad antivirica.
AU5710896A (en) Intrapulmonary delivery of hematopoietic drug
AU6712090A (en) Drug delivery systems and matrix therefor
FI972949A0 (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
DK89592D0 (da) Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
WO1992019209A3 (en) Taste-masked medicaments and their preparation
FI944229A (fi) Astyylisalisyylihappoon tai sen suoloihin perustuva puristettu farmaseuttinen annosmuoto oraalista antoa varten ja menetelmä sen valmistamiseksi
CA2184395A1 (en) Effective dosage form for antiepileptic drugs
TR199701463T1 (en) Sorbin asiti i�eren hidrojel.
EP0408019A3 (en) Pharmaceutical active derivative delivery systems
AU6369290A (en) Improved spray formulation for the testing of smoke detectors and delivery system therefor
MX9605190A (es) Forma de dosis efectiva para farmacos antiepilepticos.
ATE94382T1 (de) Adhaesives mittel zur arzneistoffabgabe.
SI0808158T1 (en) Medicament form for the delivery of active substances to wounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SUPERNUS PHARMACEUTICALS, INC., ROCKVILLE, MD., US